Research programme: therapeutic HSV-2 vaccines - Profectus Biosciences
Latest Information Update: 27 Jul 2016
At a glance
- Originator Profectus Biosciences
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Herpes simplex virus type 2 infections
Most Recent Events
- 27 Jul 2016 Early research in Herpes simplex virus type-2 infections in USA (Parenteral)